Stock Ratings / Health Care / HCWB / insiders

PRFX (39) SBFM (44) APVO (46) SILO (19) ⌘ Pro Terminal →

HCW Biologics Inc. (HCWB) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Are HCWB insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies HCWB leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

$1.18 -3.28% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

HCW Biologics Inc. (HCWB) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $2.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-13.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HCWB)Realized 20D OHLCV Swing Band: ±12.5%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

HCWB Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (HCWB)

No recent open-market Form 4 cluster sales or emergency dumps flagged on HCWB. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HCWB)

✓Walkthrough of HCWB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HCWB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -58.30%⚡ TESTING RESISTANCE

2026-10-30O $1.16H $1.19L $1.10C $1.18VOL 34.5K

RES: $2.33SUP: $0.98SMA50: $1.92SMA200: $4.12

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HCWB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HCWB Butterfly Map → + Track HCWB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HCWB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HCWB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HCWB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HCWB)

Health Care Rank #982 of 1016 ⚔️ PRFX vs HCWB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HCWB vs. PRFX, SBFM, APVO, SILO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, HCW Biologics Inc. (HCWB) ranks #982 by composite RQD confidence (27/100, grade E) and #983 by equity capitalization ($2.6M). Within this direct 5-issuer industry benchmark cohort, HCWB leads on earnings valuation at N/A trailing P/E, while SBFM leads on capital efficiency and profitability with -21.4% ROIC and 33.8% gross margin. APVO currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with HCWB at 27/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HCWB ACTIVE HCW Biologics Inc.	E	27/100	—	20.0%	-35.0%	-3.28%	$2.6M	Benchmark Subject
PRFX PRF Technologies Ltd.	D-	39/100	—	-30.0%	-35.0%	-3.86%	$2.6M	/prfx-vs-hcwb →
SBFM Sunshine Biopharma Inc.	D	44/100	—	33.8%	-21.4%	+7.07%	$2.5M	/sbfm-vs-hcwb →
APVO Aptevo Therapeutics Inc.	D	46/100	—	—	-35.0%	+4.62%	$2.5M	/apvo-vs-hcwb →
SILO Silo Pharma Inc.	E	19/100	—	38.6%	-35.0%	-6.72%	$2.4M	/silo-vs-hcwb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001828673

In its most recent audited fiscal period (FY2025, filed 2025-12-31), HCW Biologics Inc. (HCWB) reported GAAP revenue of $54.2K (-97.9% vs. FY2024 revenue of $2.6M ) , GAAP net income of -$8.0M, operating cash flow of -$13.4M, and free cash flow of -$13.4M (+7.6% YoY). On the balance sheet, HCWB closed FY2025 with $24.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$54.2K	-$8.0M	-$13.4M	-$13.4M	$24.5M	—
FY2024 (FY)	2024-12-31	$2.6M	-$30.0M	-$14.2M	-$14.5M	$30.2M	—
FY2023 (FY)	2023-12-31	$0	-$25.0M	-$22.5M	-$22.5M	—	—

3. HCWB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HCWB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, HCW Biologics Inc. (NASDAQ: HCWB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $1.18 (-3.28% 1D, market cap $2.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, HCWB ranks #982 in composite RQD confidence.

How does HCWB compare to PRFX and SBFM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HCWB carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 20.0%, and ROIC of -35.0%. By comparison, PRFX (PRF Technologies Ltd.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $2.6M) and SBFM (Sunshine Biopharma Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -21.4%, cap $2.5M). Among the 5-stock peer group, HCWB leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HCWB?

Per HCWB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001828673), HCW Biologics Inc. generated $54.2K in revenue (-97.9% YoY), -$8.0M in net income, and -$13.4M in free cash flow against $24.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HCWB trading relative to its 50-day, 200-day, and 52-week technical levels?

HCWB last traded at $1.18 (-3.28% on volume of 33,448 shares), positioning the stock -38.54% below its 50-day simple moving average ($1.92) and -71.36% below its 200-day simple moving average ($4.12). Across its 52-week range of $1.09 to $23.94, HCWB sits at the 0.4% percentile with a 14-day RSI of 31.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.03 to $1.33).

HCWB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are HCWB insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies HCWB leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: HCWB RQD Cockpit HCWB 12M Forecast HCWB Earnings & Move HCWB Dividends & DRIP HCWB Insiders & 13F HCWB Whale Options HCWB Profit Sankey HCWB News & Why